ADAMTS13 and thrombotic thrombocytopenic purpura: Of those, up to 90% of the TTP cases are classified as immune-mediated TTP (iTTP), resulting from the acquired production of anti-ADAMTS13 autoantibodies [5,6] while the remaining patients suffer from TTP of unknown cause (uTTP) [7,8].